Michael Heffernan

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Sonia S. Anand, Jackie Bosch, John W. Eikelboom et al. · The Lancet · 2017 · 855 citations · Full text

Thrombosis, Cardiovascular Disease, Stroke +13

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

C.E.M. Griffiths, Kristian Reich, Mark Lebwohl et al. · The Lancet · 2015 · 815 citations

Randomised Trials, Clinical Trials, Clinical Dermatology +5

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Stuart J. Connolly, John W. Eikelboom, Jackie Bosch et al. · The Lancet · 2017 · 749 citations · Full text

Thrombosis, Cardiovascular Disease, Atherosclerosis +12

Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction

Warren J. Cantor, David Fitchett, Bjug Borgundvaag et al. · New England Journal of Medicine · 2009 · 578 citations

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

Kenneth B. Gordon, Richard G. Langley, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology · 2006 · 502 citations

Open-label Extension Study, Systemic Treatment, Severe Psoriasis +6